In order to meet corporate demands and adapt to the development trend of the industry, Longtime Pharmaceutical, a subsidiary of Nenking Group, officially moved to a new headquarter on March 23, 2022, and held a grand launching ceremony. For Longtime, this relocation not only leaves its own mark throughout the development process, but also means that the company starts a new journey and officially marches ahead to be a larger biopharmaceutical enterprise with higher standards, richer technologies and bigger scales.
As the controlling shareholder of Longtime Pharmaceutical, Zhong Naixiong, honorary chairman of the board of directors of Nenking Group, attended the relocation ceremony and the opening ceremony together with Fu Tingling, vice chairman and general manager of Longtime, Ye Chunhua, deputy general manager, and Teng Ling, deputy general manager as well as Xu Yifan, chief financial officer.
At the ceremony, Fu Tingling, vice chairman and general manager of Longtime Pharmaceutical, spoke on behalf of the board of directors and management of the company. Mr. Fu said that since the establishment in 2003 and through over ten years of hard work, Longtime has built its main product “Gaifu” into a major brand of growth factor products. In the future, Longtime will become the leading enterprise of growth factors and we will continue to uphold the enterprise spirit of “Innovation and Excellence”, and the core values of “Diligence, Simplicity and Perseverance”. Moreover, by focusing on the biopharmaceutical development strategy, and continue to make overall improvements to land more projects, Longtime will spare no efforts to be a model enterprise in the biopharmaceutical industry in the next five years. In terms of industrialization, the company will accelerate production automation and intelligence, continuously enhance product quality standards, achieve energy conservation and consumption reduction and reduce production costs. At the same time, Mr. Fu also mentioned that the relocation of the headquarter and production base will provide good development conditions and serves as a strong support for the company to move to the next level.
Through 19 years of unremitting efforts, Longtime starts from scratch and now it owns a workshop with a capacity of more than 4.2 million and a new one with over 11 million capacities. It has gradually grown into a biopharmaceutical enterprise with core competitiveness in the field of growth factors. In the future, with the assistance of the new production base and the industry status of “Gaifu”, Longtime will step up on innovation and make strategic layouts for expanding new indications and preparations of growth factors.